Latest News

Stay up to date on the latest developments at Oncurious. Be sure to check in regularly for updates and press releases on ongoing research and clinical trials or just subscribe to our mailing list to receive regular updates.

 

 

  • 1 Sep 2017
    ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB
  • 17 Jan 2017
    ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma
  • 2 May 2016
    Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma
  • 15 Mar 2016
    Oncurious NV and BioInvent Partner with US Research Consortium to accelerate Phase I/IIa clinical development of TB-403
  • 7 Jan 2016
    Oncurious NV Announces FDA Acceptance of Investigational New Drug (IND) Application for a Phase I/IIa Study with TB-403 for the Treatment of Pediatric Brain Tumors
  • 2 Sep 2015
    Oncurious NV Launches New Website
  • 26 Jun 2015
    Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
  • 14 Apr 2015
    ThromboGenics and VIB launch New Oncology Company Oncurious NV to develop TB-403 for Pediatric Brain Tumors